Advertisement

Journal of Neuro-Oncology

, Volume 113, Issue 2, pp 341–342 | Cite as

Unclear standard of care for pediatric high grade glioma patients

  • Jason Fangusaro
  • Katherine E. Warren
Letter to the Editor

To the Editor

Pediatric high grade gliomas (HGGs) are aggressive tumors with an unclear standard of care. However, there are many agreed upon treatment standards. The amount of surgical resection is one important clinical prognostic factor identified [1, 2]. The Children’s Cancer Group (CCG) study-945 revealed children who underwent a surgical resection of 90 % or greater had 5-year progression-free survival (PFS) of 35 + 7 % compared to 17 + 4 % in patients who did not [1]. Every attempt should be made at a complete surgical resection when safe to maximize survival. Also, for most children greater than 3 years old, focal radiotherapy has become standard. One of the main unanswered questions regarding the standard of care, however, surrounds the uncertain role of chemotherapy.

Children’s Cancer Group study-943 randomized children to either weekly vincristine during radiation (XRT) (54 Gy) followed by maintenance prednisone, lomustine, and vincristine (pCV) or XRT alone [3]. Five-year...

Keywords

Bevacizumab Temozolomide Vorinostat High Grade Glioma Patient Pediatric High Grade Glioma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

  The authors declare no conflicts of interest.

References

  1. 1.
    Finlay JL et al (1995) Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen Childrens Cancer Group. J Clin Oncol 13(1):112–123PubMedGoogle Scholar
  2. 2.
    Cohen KJ et al (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol 13(3):317–323PubMedCrossRefGoogle Scholar
  3. 3.
    Sposto R et al (1989) The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 7(2):165–177PubMedCrossRefGoogle Scholar
  4. 4.
    Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Pediatric Neuro-OncologyAnn and Robert H. Lurie Children’s Hospital of ChicagoChicagoUSA
  2. 2.Pediatric Oncology BranchNational Cancer InstituteBethesdaUSA

Personalised recommendations